4.33
-0.17(-3.78%)
Currency In USD
Previous Close | 4.5 |
Open | 4.5 |
Day High | 4.53 |
Day Low | 4.25 |
52-Week High | 6.26 |
52-Week Low | 0.64 |
Volume | 85,613 |
Average Volume | 153,809 |
Market Cap | 19.75M |
PE | -3.38 |
EPS | -1.28 |
Moving Average 50 Days | 4.62 |
Moving Average 200 Days | 2.59 |
Change | -0.17 |
If you invested $1000 in Lixte Biotechnology Holdings, Inc. (LIXT) 10 years ago, it would be worth $451.04 as of October 21, 2025 at a share price of $4.33. Whereas If you bought $1000 worth of Lixte Biotechnology Holdings, Inc. (LIXT) shares 5 years ago, it would be worth $62.21 as of October 21, 2025 at a share price of $4.33.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
GlobeNewswire Inc.
Oct 16, 2025 12:00 PM GMT
Company underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Na
LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions
GlobeNewswire Inc.
Sep 10, 2025 8:05 PM GMT
BOCA RATON, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has made an initial purchase of cryptocurrencie
24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor
Newsfile
Sep 05, 2025 12:35 PM GMT
Unlocking a New Era in Cancer TreatmentDenver, Colorado--(Newsfile Corp. - September 5, 2025) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, underscores the scie